The kinase Fyn mediates levodopa induced dyskinesias in Parkinson´s disease
Objective: To pharmacologically manipulate the kinase Fyn as a novel target to control levodopa induced dyskinesias. Background: The management of levodopa induced dyskinesias (LID) in…Olfaction and gray matter volume in Parkinson’s disease. A voxel-based morphometry study
Objective: To evaluate the relation between olfactory functioning and gray matter (GM) volume in patients with Parkinson's disease (PD). Background: Olfactory impairment is one of…A novel C. elegans model for identification of small molecules that target alpha-synuclein-mediated toxicity
Objective: To develop a novel transgenic C. elegans model to study dopaminergic neurodegeneration mediated by alpha-synuclein. Background: Targeting alpha-synuclein could be a disease-modifying strategy for…Differential expression of cerebral dopamine neurotrophic factor (CDNF) in the hippocampus and in the striatum of LRRK-2 mutant rat model of Parkinson’s disease
Objective: The objective of our study was to characterize the behavioral phenotype of the transgenic LRRK-2 rat in the context of PD model and to…Brain metabolic profile changes reflect subtle pathological alterations in different murine models of Parkinson’s disease
Objective: Understanding early, and therefore often subtle, disease processes in Parkinson's disease (PD) is essential for the development of disease modifying cures. But in patients,…Enteric neurons reveal substantial in vivo mitochondrial changes in Parkinson’s disease
Objective: Study in vivo mitochondrial and ganglionic morphometrics of enteric neurons in Parkinson's disease. Background: While well established in autopsy studies, the crucial role of…Characterization of striatal TH-immunoreactive cells in chronic and acute L-DOPA treatment in a mice model of Parkinson´s disease
Objective: To characterize Tyrosine Hydroxylase immunoreactive cells (TH-ir) in a mouse model of hemiparkinsonism and L-DOPA induced dyskinesia. Background: L-DOPA-induced dyskinesias (LID) are a severe…Striatal PDE10 expression in Parkinson’s disease (PD) and healthy controls using [18F]MNI-659 PET imaging
Objective: To evaluate the feasibility of [18F]MNI-659 PET, a striatal PDE10A imaging tracer, as a imaging biomarker in PD. Background: PDE10 is highly and specifically…Longitudinal cerebrospinal fluid biomarkers in early Parkinson’s disease and healthy controls
Objective: To analyze changes in levels of four distinct biomarkers in drug-naïve Parkinson's disease (PD) subjects in cerebrospinal fluid (CSF) over 6- and 12 mo…Valproate-associated parkinsonism – A critical review of the literature
Objective: To provide a critical review of the existing literature on valproate-associated parkinsonism and to discuss possible mechanisms. Background: Valproate was first approved as an…
- « Previous Page
- 1
- …
- 146
- 147
- 148
- 149
- 150
- …
- 207
- Next Page »